LSO Breakfast Series

As Psychedelics remain a restricted recreational substance in Canada, Health Canada has granted some exceptions allowing individuals seeking therapy to use these substances as medical treatment. The resurgence of this medicine as a treatment for mental health and terminal illness has attracted growing interest from the scientific and medical communities.

Join LSO and our panel of speakers for an engaging webinar on the history of psychedelics in medicine, breaking the stigma. Why the science makes sense, and why it’s made a resurgence in medicine once again.

Speakers:

• David Wood, Chief Legal Officer, and General Counsel, Psygen Industries Ltd
• David Clements, Executive Director, Psychedelics Research & Senior Advisor, Innovation Strategy and Policy at Queen's University - Faculty of Health Sciences
• Lakshmi P. Kotra, Professor, Leslie Dan Faculty of Pharmacy, University of Toronto; Senior Scientist, University Health Network, and CEO, Lucid Psycheceuticals (subsidiary of FSD Pharma)
• Deb Russelo O'Neill, Patient Advocate

Sponsored by:

FSD Pharma Inc. is a biotechnology company with three drug candidates in different stages of development. FSD BioSciences, Inc. (“FSD BioSciences”), a wholly owned subsidiary, is focused on pharmaceutical research and development of its lead compound, ultra-micronized palmitoyl ethylamine (“PEA”) or FSD-PEA (formerly called FSD-201). Lucid Psycheceuticals Inc. (“Lucid”), a wholly owned subsidiary, is focused on the research and development of its lead compounds, Lucid-PSYCH (formerly Lucid-201) and Lucid-MS (formerly Lucid-21-302). Lucid PSYCH is a molecular compound identified for the potential treatment of mental health disorders. Lucid-MS is a molecular compound identified for the potential treatment of neurodegenerative disorders.